In addition, preliminary evidence for reduced bleeding was observed, with a 49-100 percent reduction in estimated ABR during the observation period compared with pre-study values. Dose escalation has ...

The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...

Please provide your email address to receive an email when new articles are posted on . The subcutaneously administered small interfering RNA therapy conferred a 90.8% reduction in the annualized ...

Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to ...

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding ...

The use of adjunctive topical tranexamic acid (TXA) showed benefits in significantly reducing postoperative bleeding with second intention healing, or allowing wounds to heal naturally without sutures ...

On Friday, Novo Nordisk A/S (NYSE:NVO) said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending approval of Alhemo ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody significantly reduced both treated spontaneous and traumatic bleeds among individuals ...

Findings from the Phase 3 study were presented at the 67 th American Society of Hematology Annual Meeting and Exposition and published in Blood The findings were shared today in an oral presentation ...